Life Sciences Ontario’s Post

🌟 Pharmster Reflection: Celebrating the Unparalleled Brilliance of Pharma Minds! 💊🌐 Greetings Esteemed Pharmster Family! 🌟👋 Today, let's take a profound moment to recognize the exceptional qualities that distinguish us—the brilliant minds hailing from the pharmaceutical world. 💙💡 🌱 Scientific Curiosity: In the realm of pharmaceuticals, our collective spirit is driven by an insatiable curiosity for the scientific intricacies of medicines. It's this innate spark that propels us to seek, question, and innovate—a commitment to perpetual learning in the ever-evolving landscape of healthcare. 🧪📚 💼 Precision and Accuracy: Amidst the challenges we face, our commitment to precision sets us apart. Whether compounding medications, conducting groundbreaking research, or ensuring patient safety, our unwavering attention to detail defines the gold standard in pharmaceutical excellence. 🎯💊 👥 Compassionate Care: Beyond the technicalities, we recognize the human side of healthcare. Our distinctive blend of scientific expertise and compassionate care positions us as not just professionals but healers with a heart. Each interaction is an opportunity to make a meaningful impact. ❤️👩⚕️ 🌍 Global Impact: Our contributions transcend borders. From the development of life-saving medications to active participation in global health initiatives, the work we do reverberates globally. We are interconnected, collectively making a profound difference in communities far and wide. 🌍🌐 💙 The Pharmster Anthem: Pharmster family, let's not only celebrate our brilliance but also recognize the intrinsic value we bring. We are not just professionals; we are architects of health. In acknowledging our worth, we set a standard that no one can overlook. It's a call to value ourselves above all else, establishing a benchmark that elevates the entire field. So, as we take pride in our unique role in the pharmaceutical world, let's also reflect on the importance of self-valuation. 🌟 Tap the like button & follow if you resonate with the spirit of Pharmster pride! 🚀💙 #PharmsterPride #PharmaExcellence #ValueYourImpact #RisingAboveTheNorms

How should IP (in-house) layers deal with the groundbreaking implications of the IRA? Listen in! We were pleased to welcome Henry Hadad of Bristol Myers Squibb, who joined our #LifeSciences and #HealthCare team for our recent webinar presentation on why IP lawyers should care about the U.S. Inflation Reduction Act. In this article, our lawyers highlight key takeaways from the webinar. #intellectualproperty

In a new opinion in the Daily News, NCLifeSci President Laura Gunter and Director of @IncubateCoalition John Stanford highlight how the Ensuring Pathways to Innovate Cures (EPIC) Act would protect investments in new medication development. The legislation would address a provision within the Inflation Reduction Act that implemented differing price negotiation eligibility timelines between small and large molecule medicines, leading to fewer incentives to research, develop, and commercialize certain medications. Learn more about why the #EPICAct is a critical step to support North Carolina’s life sciences industry: https://bit.ly/3VWGbx5

We were pleased to welcome Henry Hadad of Bristol Myers Squibb, who joined our #LifeSciences and #HealthCare team for our recent webinar presentation on why IP lawyers should care about the U.S. Inflation Reduction Act. In this article, our lawyers highlight key takeaways from the webinar. #intellectualproperty

C6 Patient Recruitment co-founders Dave Beaulieu and Howard (Howie) Levy launched the company to help clinical researchers enroll the right patients faster, more efficiently, and at the right cost for clinical research sites. We’re successful because of three key distinctions that differentiate our services from those of traditional recruiting firms: ☑ A localized, site-branded approach ☑ Cross-industry marketing experience translated into proven methodologies and purpose-built technologies ☑ Incentive alignment and transparency Learn more about our innovative approach here: https://lnkd.in/eq2TNAND  #ClinicalTrials #ClinicalResearch #Pharma #PatientRecruitment #HealthTech #DrugDevelopment

Biopharma engagement with Integrated Health Systems has increased in importance and complexity, giving companies opportunities to enhance the effectiveness and efficiency of engaging these IDNs. What are the critical success factors of a core IDN strategy? What are IDNs' recent sentiments towards biopharma? Learn all of this and more at Syneos Health's Critical Success Factors of Integrated Health System Engagement panel at the Informa Connect Health Systems & Pharma Partnering 2023 Summit. #InformaConnect #IDNs #SyneosHealth

Market Access Mindset: Missteps Companies Make with Market Access. During our tenure as biopharma executives, and now as advisors, we have observed, first-hand, very common missteps organizations make when building and executing their market access strategies. In fact, we haven’t just seen them, we have made some of these mistakes ourselves.   ●      Initiating market access activities far too late (i.e., after pivotal trial results are known). ●      Over indexing on input from physicians and regulatory authorities at the expense of hearing from payers, patients, and other influential stakeholders.  ●      Assuming premium pricing is achievable based on modest, incremental clinical benefits, unique mechanisms of action, and/or simple delivery and convenience advantages.  ●      Failure to establish unique value propositions for each indication and unique stakeholder group. ●      Relying on novel pricing models as an “easy way” to address misalignments between price and value. ●      Focusing solely on the launch list price without understanding and planning for mandatory discounts and price concessions that result from payer actions and competitive dynamics. ●      Failing to plan for future pricing complexities due to a medicine’s follow-on indications. ●      Not leveraging distribution for BOTH strategic and financial value.   These common missteps often lead to unnecessary access barriers for patients, provider frustration and lagging sales performance. Want to learn from our experience and avoid these common pitfalls?  E-mail us at [email protected] #marketaccessmindset #marketaccess #a3access #biotech

In Parexel's latest edition of the New Medicines, Novel Insights newsletter, @Alex Gee, Senior Director, Parexel Access Consulting, shares the keys to establishing market access, why patient insights are essential, and how every drug developer can benefit from bringing access experts in by phase II. Learn how to demonstrate clinical and economic value, positioning your product for favorable coverage decisions that benefit the appropriate patient population. Like and subscribe to stay updated with more #NovelInsights! #MarketAccess #PatientEngagement #Reimbursement #HealthEconomics

Loooking forward to this update webinar!